Global Network Point-of-Care Glucose Testing Market Set to Reach USD 2.5 Billion by 2032, Driven by Rise in Remote Patient Monitoring and Technological Advancements | FMI

The global network point-of-care glucose testing market is poised for significant expansion over the next decade, according to a new study conducted by Future Market Insights (FMI). The report estimates the market was valued at USD 1.6 Billion in 2022, and is expected to grow steadily at a CAGR of 4.8%, reaching USD 2.5 Billion by 2032. The market is witnessing dynamic evolution driven by increased emphasis on remote patient monitoring, growing prevalence of diabetes, and the surge in point-of-care diagnostics integrated with digital health ecosystems.

Among the leading products in the market, Accu-Chek Inform II has shown a robust growth trajectory, registering a CAGR of 4.8% during the forecast period (2022-2032), underlining the increasing demand for accurate and connected glucose monitoring tools in clinical and remote care settings.

Stay Ahead with Market Trends: Access Your Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3135383630

Remote Monitoring Fuels Market Momentum

As healthcare continues to shift toward personalized and preventive care, there is a growing demand for diagnostic tools that can offer real-time data and seamless communication between patients and healthcare providers. Network point-of-care glucose testing devices stand at the forefront of this revolution, enabling clinicians to access patient data remotely and deliver timely interventions, especially for individuals living with chronic conditions such as diabetes.

The COVID-19 pandemic further accelerated the adoption of remote patient monitoring technologies, encouraging hospitals, clinics, and home care providers to implement smart glucose monitoring systems that can be seamlessly integrated into hospital information systems (HIS) and electronic medical records (EMR).

Key Takeaways: Network Point-of-Care Glucose Testing Market Analysis

• USA Market Insights:
  • Valued at USD 735 million by 2032, the U.S. market experienced a 4.6% CAGR from 2017 to 2021.
  • Forecasted to grow at 4.9% CAGR through 2032, generating an absolute dollar opportunity of USD 276.2 million.
  • The increasing prevalence of diabetes (affecting 37.3 million Americans in 2019, including 8.5 million undiagnosed) is driving demand for point-of-care testing.
  • Leading player Abbott remains dominant with its FreeStyle Libre 2 CGM system, widely adopted by U.S. consumers for real-time glucose tracking.
• United Kingdom Market Overview:
  • Expected to reach USD 119 million by 2032, growing at a CAGR of 5.8%.
  • Estimated to register an absolute dollar opportunity of USD 50.6 million over the forecast period.
• Japan Market Overview:
  • Set to hit USD 101 million by 2032 with a CAGR of 4.5%.
  • Poised to deliver an absolute dollar opportunity of USD 36 million from 2022 to 2032.
• South Korea Market Overview:
  • Projected market value of USD 59 million by 2032, with a CAGR of 4.9%.
  • Anticipated absolute dollar opportunity of USD 23 million during the forecast period.

Innovative Product Launches Reinforce Industry Leadership

Major industry players are actively engaged in launching next-generation glucose testing systems that support digital integration, connectivity, and user-friendly interfaces. One notable development is from F. Hoffmann-La Roche Ltd, a key player in the diagnostics market. In January 2022, Roche launched the Cobas pulse system, a revolutionary networked diagnostic device that not only provides point-of-care blood glucose readings but also enables interaction with digital health software developers. Designed to simplify clinical workflows, the Cobas pulse system is intended to enhance decision-making, improve care coordination, and ultimately deliver better patient outcomes.

This innovation reflects a broader industry trend where diagnostic device manufacturers are aligning with digital health platforms to transform care delivery models and meet the growing expectations of both providers and patients.

Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights! https://www.futuremarketinsights.com/reports/network-point-of-care-glucose-testing-market

Key Players Driving Market Expansion

The global network point-of-care glucose testing market features a competitive and innovation-driven landscape. Key companies operating in the space include:

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Abbott Laboratories
• Nipro Corporation
• Platinum Equity Advisors, LLC (Lifescan, Inc.)
• Nova Biomedical
• ACON Laboratories
• Trividia Health, Inc.
• Prodigy Diabetes Care, LLC
• Bayer AG/Ascensia Diabetes Care Holdings AG
• EKF Diagnostics

These companies are heavily investing in R&D, forging strategic partnerships, and promoting diabetes awareness globally. The ultimate goal is to empower patients and caregivers with tools that ensure accurate, fast, and network-enabled testing—essential for disease management and therapeutic decision-making.

Segment Analysis: Product and Regional Insights

By Product Type:

The market is segmented into several prominent products, each catering to specific clinical needs:

• i-STAT
• Accu-Chek Inform II
• Stat Strip
• Hemo Cue
• CareSens Expert Plus
• BARO-zen H Expert Plus

Among these, Accu-Chek Inform II continues to dominate due to its clinical accuracy, connectivity features, and wide hospital network integration. Devices like Stat Strip and CareSens Expert Plus are also gaining traction due to their ease of use, low sample requirement, and rapid turnaround times, making them highly suitable for critical care environments.

By Region:

The global market is geographically segmented as follows:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

North America currently leads the market, driven by advanced healthcare infrastructure, widespread adoption of digital health tools, and strong regulatory support for innovation in diagnostics. Europe and East Asia follow closely, with rising healthcare investments and an increasing diabetic population.

Meanwhile, South Asia and Africa are emerging as high-potential growth markets, supported by increasing public and private sector initiatives aimed at improving access to diagnostics and chronic disease management tools in underserved regions.

Market Outlook: A Future Anchored in Innovation and Access

As the global healthcare landscape shifts toward value-based care, the need for connected diagnostic systems like network point-of-care glucose testing is becoming more apparent. These systems not only enhance diagnostic efficiency but also play a pivotal role in patient engagement and clinical decision support.

According to Future Market Insights, the future of the market lies in:

• Integration with mobile health (mHealth) platforms
• Cloud-based data storage and analysis
• Artificial intelligence (AI)-driven decision tools
• Greater focus on home-based and decentralized care settings

With growing attention on early detection, chronic care management, and data-driven insights, networked glucose testing devices are expected to become a cornerstone of smart healthcare systems worldwide.